0RPS Medicover Ab

STOCKHOLM, Feb. 11, 2022 /PRNewswire/ --

Fourth quarter

• Revenue amounted to €376.3m (€297.7m), an increase of 26.4% with an organic growth of 21.6%.
• Operating profit (EBIT) was €41.6m (€29.9m), representing an operating margin of 11.1% (10.1%).
• Net profit amounted to €28.4m (€18.8m), which represents a net profit margin of 7.6% (6.3%).
• EBITDA was €75.1m (€53.1m), an increase by 41.6%. EBITDA margin was 20.0% (17.8%).
• EBITDAaL amounted to €56.9m (€41.2m), corresponding to an EBITDAaL margin of 15.1% (13.9%).
• Net cash flow from operating activities was €53.9m (€39.0m).
• Basic/diluted earnings per share were €0.186 (€0.123).

Full year

• Revenue amounted to €1,377.4m (€997.8m), an increase of 38.0% with an organic growth of 38.1%.
• Operating profit (EBIT) was €159.4m (€61.3m), representing an operating margin of 11.6% (6.1%).
• Net profit amounted to €106.6m (€27.3m), which represents a net profit margin of 7.7% (2.7%).
• EBITDA was €270.4m (€157.5m), an increase by 71.7%. EBITDA margin was 19.6% (15.8%).
• EBITDAaL amounted to €210.8m (€108.5m), corresponding to an EBITDAaL margin of 15.3% (10.9%).
• Net cash flow from operating activities was €216.7m (€155.1m).
• Basic/diluted earnings per share were €0.686 (€0.182).
• The board of directors proposes a dividend for 2021 of €0.12 (€0.07) per share.             

REVENUE AND EARNINGS

Definition and reconciliation of alternative performance measures are available at www.medicover.com/financial-information.

This interim report has not been subject to review by the Company's auditor.

This is information that Medicover AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication through the agency of the contact person set out below at 7.45 (CET) on 11 February 2022. This year-end report and other information about Medicover is available at medicover.com.

For full report, see attached pdf.

Financial Calendar
Annual report                                                                                               week 13
Interim report January-March                                                                      27 April
Annual general meeting                                                                              27 April
Interim report April-June                                                                              22 July
Interim report July-September                                                                    3 November

For further information, please contact:

Hanna Bjellquist, Head of Investor Relations
Phone: +46 70 303 32 72
E-mail: hanna.bjellquist@medicover.com

Conference call: A conference call for analysts and investors will be held today at 09.30 CET. To listen in please register here. To ask questions please dial in and use code: 4597901

SE: +46 (0)8-566 184 67   
DE: +49 (0) 305 200 2085
UK: +44 (0) 2071 928 338
US: +1 646 741 3167

Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities,laboratories and blood-drawing points and the largest markets are Poland and Germany. In 2020, Medicover had revenue of EUR 998 million and more than 32,000 employees. For more information, go to www.medicover.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medicover/r/year-end-report-january-december-2021,c3504433

The following files are available for download: